Transfusion-associated graft-versus-host disease;Reakcija transplantata protiv primatelja uzrokovana transfuzijom

Lijecnicki Vjesnik

Volumn 126, Issue 1-2, 2004, Pages 39-47

  Bojanić, Ines ^a,b   Ćepulić, Branka Golubić ^a  

^a KBC Zagreb   (Croatia)

^b Zavod za Imunologiju   (Croatia)

Author keywords

Blood transfusion adverse effects; Graft vs host disease etiologija

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; DACLIZUMAB; HISTOCOMPATIBILITY ANTIGEN; NAFAMSTAT MESILATE; OKT 3; SERINE PROTEINASE INHIBITOR; STEROID; THYMOCYTE ANTIBODY;

BLEEDING; BLOOD TRANSFUSION; BONE MARROW APLASIA; BONE MARROW DEPRESSION; CELL VIABILITY; FATALITY; GAMMA IRRADIATION; GASTROINTESTINAL DISEASE; GRAFT VERSUS HOST REACTION; HIGH RISK POPULATION; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LIVER DYSFUNCTION; LYMPHOCYTE COUNT; LYMPHOCYTE PROLIFERATION; REVIEW; SKIN DISEASE; T LYMPHOCYTE;

BLOOD TRANSFUSION; GRAFT VS HOST DISEASE; HUMANS;

EID: 3142662592     PISSN: 00243477     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. Billingham RE. The biology of graft-vs-gost reactions. Harvey Lect 1966; 67:62:21-78.
2. Mathe G, Bernard J, Schwarzenberg L. New trials with homologous bone marrow grafts after total irradiation in children with acute leukemia in remission. The problem of the secondary syndrome in man. Revues Hematologique (Paris) 1960;15:115-61.
3. Shimoda T. On postoperative erythroderma. Geka 1955;17:487-92.
4. Hathaway WE, Brangle RW, Nelson TL, Roeckel IE. Aplastic anemia and alymphocytosis in an infant with hypogammaglobulinemia: Graft-vs-host reaction? J Pediatr 1966;68:713-22.
5. Aoki Y, Nakamura H, Sakakibara Y. Probable graft-versus-host reaction following massive blood transfusion in an aged patient with postoperative aortic aneurysm: a case report. Nippon Naika Gakkai Zasshi 1984;73: 1209-16.
6. Ito K, Fujita M, Norioka M i sur. Postoperative erythroderma with change of HLA phenotypes from heterozygotes to homozygotes: report of two cases. Eur J Haematol 1991;46:217-22.
7. Golumy E, Schipper R, Pool J i sur. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med 1996;334:281-5.
8. Shivdasani RA, Hluska FG, Dock NL i sur. Graft-vs-host disease associated with transfusion of blood from unrelated HLA-homozygous donors. N Engl Med 1993;328:766-70.
9. Shivdasani RA, Anderson KC. HLA homozygosity and shared HLA haplotypes in the development of transfusion-associated graft-vs-host disease. Leuk Lymphoma 1994;15:227-34.
10. Lee TH, Donegan E, Slichter S, Busch MP. Transient increase in circulating donor leukocytes after allogenic transfusions in immunocompetent recipients compatible with donor cell proliferation. Blood 1995;85: 1207-14.
11. Webb IJ, Kenneth CA. Transfusion-associated graft-vs-Host Disease. In: Popovsky MA, ed. Transfusion reactions, Bethesda, MD: AABB Press, 2001:171-86.
12. Ferrara JLM, Antin JH. The pathophysiology of graft-versus-host disease. In: Thomas ED, Blume KG, Forman SJ, ed: Hematopoietic cell transplantation. Oxford: Blackwell Science, 1999:305-15.
13. Ferrara JL, Krenger W. Graft-vs-host disease: the influence of type 1 and type 2 T cell cytokines. Transfus Med Rev 1998;12:117.
14. Antin JH, Ferrera JL. Cytokine dysregulation and acute graft-vs-host disease. Blood 1992;80:2964-8.
15. Nishimura M, Uchida S, Mitsunaga S i sur. Characterisation of T-cell clones derived from peripheral blood lymphocytes of a patient with transfusion-associated graft-versus-host disease: Fas-mediated killing by CD4+ and CD8+ cytotoxic T-cell clones and tumor necrosis factor beta production by CD4+ T-cell clones. Blood 1997;89:1440-5.
16. Ohto H, Anderson KC. Survey of transfusion-associated graft-versus-host disease in immunocompetent recipients. Transfus Med Rev 1996;10: 31-4.
17. Wagner FF, Flegel WA. Transfusion-associated graft-versus-host disease: risk due to homozygous HLA haplotypes. Transfusion 1995;35:284-91.
18. Goodnough LT, Johnston MF, Ramsey G i sur. Guidelines for transfusion support in patients undergoing coronary artery bypass grafting. Ann Thorac Surg 1990;50:675-83.
19. Petz LD, Calhoun L, Yam P i sur. Transfusion-associated graft-vs-host disease in immunocompetent patients: Report of a fatal case associated with transfusion of blood from a second-degree relative, and a survey of predisposing factors. Transfusion 1993;33:742-50.
20. Mincheff M. Changes in donor leukocytes during blood storage. Implications on posttransfusion immunomodulation and transfusion-associated GVHD. Vox Sang 1998;74:189-200.
21. Chang H, Voralia M, Bali M, Sher GD, Branch DR. Irreversible loss of donor blood leucocyte activation may explain a paucity of transfusion-associated graft-versus-host disease from stored blood. Br J Haematol 2000;111:146-56.
22. Weiding JU, Vehmeyer D, Dittman J i sur. Contamination of fresh-frozen plasma with viable white cells and proliferable stem cells. Transfusion 1994;34:185-6.
23. Perkins HA. Granulocyte concentrates: should they be routinely irradiated? Prog Clin Biol Res 1981;65:49-57.
24. Benson K, Marks AR, Marshall MJ, Goldstein JD. Fatal graft-vs-host disease associated with transfusions of HLA-matched, HLA-homozygous platelets form unrelated donors. Transfusion 1994;34:432-7.
25. Mori S, Matsushita H, Ozaki K i sur. Spontaneous resolution of transfusion-associated graft-vs-host disease. Transfusion 1995;35:431-5.
26. Sanders MR, Graeber JE. Posttransfusion graft-versus-host disease in infancy. J Pediatr 1990;117:159-63.
27. Ohto H, Anderson KC. Posttransfusion graft-vs-disease in Japanese new-borns. Transfusion 1996;36:117-23.
28. Schroeder ML. Transfusion-associated graft-versus-host disease. Br J Haematol 2002;117:275-87.
29. Shivdasani RA, Anderson KC. Transfusion associated graft-vs-host disease: Scratching the surface. Transfusion 1993;33:696-7.
30. Sale GE, Shulman HM, Hackman RC. Pathology of hematopoietic cell transplantation. In: Thomas ED, Blume KG, Fomian SJ, ed: Hematopoietic cell transplantation. Oxford: Blackwell Science, 1999:248-63.
31. Hayakawa S, Chishima F, Sakata H i sur. A rapid molecular diagnosis of posttransfusion graft-vs-host disease. Transfusion 1993;33:413-7.
32. Uchida S, Wang L, Yahagi Y, Tokunaga K, Tadokoro K, Juji T. Utility of fingernail DN for evaluation of chimerism after bone marrow transplantation and for diagnostic testing for transfusion-associated graft-versus-host disease. Blood 1996;87:4015-6.
33. Strob R, Yu C, McSweeney P. Mixed chimerism after transplantation of allogenic hematopoietic cells. In: Thomas ED, Blume KG, Forman SJ, ed: Hematopoietic cell transplantation. Oxford: Blackwell Science, 1999: 287-98.
34. Yasukawa M, Shinozaki F, Hato T i sur: Successful treatment of transfusion-associated graft-versus-host disease. Br J Haemathol 1994;86:831-6.
35. Prince M, Szer J, van der Weyden MB, Pedersen JS, Holdsworth RF, Whyte G. Transfusion associated graft-versus-host disease after cardiac surgery: response to antithymocyte-globulin and corticosteroid therapy. Aust N Z J Med 1991;21:43-6.
36. Ryo R, Saigo K, Hashimoto M i sur. Treatment of post-transfusion graft-versus-host disease with nafmostat mesilate, a serine protease inhibitor. Vox Sang 1999;76:241-6.
37. Nishimura M, Hidaka N, Akaza T, Tadokoro K, Juji T. Immunosuppressive efects of chloroquine: potential effectivness for treatment of post-transfusion graft-versus-host disease. Transfus Med 1998;8:209-14.
38. Przepiorka D, Kernan NA, Ippoliti i sur Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood 2000;95:83-9.
39. Strauss RG. Data-driven blood banking practices for neonatal RBC transfusions. Transfusion 2000;40:1528-40.
40. Neiman JL, Punnett HH, Lischner HW. Possible graft-versus-host reaction after intrauterine transfusion for Rh erythroblastosis fetalis. N Engl J Med 1969;281:697-701.
41. Wise BV, Lawrence NL. A risk of blood transfusion for premature infants. MNC AM J Matren Child Nurs 1990;15:86-9.
42. Berger RS, Dixon SL. Fulminant transfusion-associated graft-vs-host disease in a premature infant. J Am Acad Dermatol 1989;20:945-50.
43. Kessinger A, Armitage JO, Klassen LW, Landmark JD, Hayes JM, Larsen AE. Graft versus host disease following transfusion of normal blood products to patients with malignancies. J Surg Oncol 1987;36:206-9.
44. Decoste SD, Boudreaux C, Dover JS. Transfusion-associated graft-vs-host disease in patients with malignancies. Report of two cases and review of the literature. Arch dermatol 1990;126:1324-9.
45. Nikoskelainen J, Soderstrom KO, Rajamaki A i sur. Graft-versus-host reaction in 3 adult leukaemia patients after transfusion of blood cell products. Scand J Haematol 1983;31:403-9.
46. Gelly KJ, Kerr R, Rawlinson S, Norris A, Bowen DT. Transfusion-associated graft vs. host disease in a patient with high grade B-cell lymphoma. Should cellular products for patients with non-Hodgkin's lymphoma be irraddiated? Br J Haematol 2000;100:228-9.
47. Munro LR, Culligan DJ, Grant A, Johnston PW, Watson HG. Transfusion-associated graft-versus-host disease in a patients with Waldenstrom's macroglobulinaemia. Vox Sang 2002;83:279-81.
48. Williamson LM, Wimperis JZ, Wood ME, Woodcock B. Fludarabine treatment and transfusion-associated graft-vs-host disease. Lancet 1996;348: 472-3.
49. Thomas ED, Herman EC, Greenough WB. Irradiation and marrow infusion in leukemia. Arch Intern Med 1961;107:829-45.
50. Postmus PE, Mulder NH, Elema JD. Graft vs host disease after transfusion of non-irradiated blood cells in patients having received autologous bone marrow: A report of 4 cases following ablative chemotherapy for solid tumors. Eur J Cancer Clin Oncol 1988;24:889-94.
51. Kennedy J, Ricketts R. Fatal graft vs host disease in a child with neuroblastoma following a blood transfusion. J Pediatr Surg 1986;21:1108-9.
52. Triuzli DJ, Nalesnik MA. Microchimerism, GVHD and tolerance in solid organ transplantation. Transfusion 2001;41:419-26.
53. Sola MA, Espana A, Redondo P i sur. Transfusion-associated acute graft-versus-host disease in a heart transplant recipient. Br J Dermatol 1995; 132:626-30.
54. Wisecarver JL, Cattral MS, Langnas AN. Transfusion induced graft versus host disease after liver transplantation. Documentation using polymerase chain reaction with HLA-DR sequence-specific primers. Transplantation 1994;58:269-71.
55. Klein C, Fraitag S, Foulon E, Raffoux C, Bodemer C, Blanche S. Moderate and transient transfusion-associated cutaneous graft-versus-host disease in a child infected by human immunodeficiency virus. Am J Med 1996; 101:445-6.
56. Habesh A, Dalgeish AG, Hounsell EF. Absence of GVHD in AIDS. J Acquir Immune Defic Syndr 1993;6:1224-7.
57. Otsuka S, Kunieda K, Kitamura F i sur: The critical role of blood from HLA-homozygous donors in fatal transfusion-associated graft-vs-host disease in immunocompetent patients. Transfusion 1991;31:260-4.
58. Takushi K, Shibata Y. Posttransfusion graft-vs-host disease in immunocompetent patients after cardiac surgery. N Engl J Med 1989;321:56.
59. Akahoshi M, Takanashi M, Masuda M i sur. A case of transfusion-associated graft-vs-host disease not prevented by white cell-reduction filters. Transfusion 1992;32:169-72.
60. Hayashi H, Nishiuchi T, Tamara H. Takeda K. Transfusion-associated graft-versus-host disease caused by leukocyte-filtered stored blood. Anesthesiology 1993;79:1419-21.
61. Pelszynski MM, Morof G, Luban ML, Taylor BJ, Quinones RR. Effect of gamma irradiation of red blood cell units on T-cell inactivation is assessed by limiting dilution analysis: implications for preventing transfusion-associated graft-versus-host disease. Blood 1994;83:1683-9.
62. BCSH. Blood Transfusion Task Force. Guidelines on gamma irradiation of blood components for the prevention of transfusion-associated graft-versus-host disease. Transfus Med 1996;6:261-71.
63. th ed. 2002:70-1.
64. th ed. Bethesda, MD: American Association of Blood Banks, 1999:30.
65. Asai T, Inaba S, Ohto H i sur. Guidelines for irradiation of blood and blood components to prevent post-transfusion graft-vs-host disease in Japan. Transf Med 2000;10:312-20.
66. Duguid JKM, Car R, Jenkins JA. Clinical evaluation of the effects of storage time and irradiation on transfused platelets. Vox Sang 1991;60: 151-4.
67. Valerius NJ, Johansen KS, Nielsen OS. Effect of vitro X-irradiation on lymphocyte and granulocyte function. Scand J Hematol 1981;27:9-18.
68. Leitner GC, Neuhauser M, Weigel G i sur. Altered intracellular purine nucleotides in gamma-irradiated red blood cell concentrates. Vox Sang 2001;81:113-8.
69. Sproul AM, Chalmers EA, Mills KI, Burnerr AK, Simpson E. Third party mediated graft rejection despite irradiation of blood products. Br J Haematol 1992;80:251-2.
70. Juji T, Takahashi K, Shibata Y, Ide H, Sakakibara T, Ino T. Post-transfusion graft-versus-host disease in immunocompetent patients after cardiac surgery in Japan. N Engl J Med 1989;321:56.
71. Hato T, Yasukawa M, Takeuchi N. Decrease in transfusion associated graft-versus-host disease. Transfusion 1994;34:457.
72. van Rhenen D, Gulliksson H, Cazenave JP i sur. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 2003;101:2426-33.